Intellectual Property

MacuSight holds a comprehensive intellectual property position covering the use of sirolimus, related compounds and other select therapeutics in the eye, as well as the company's minimally-invasive, sustained ocular formulations.

The company's intellectual property portfolio includes more than 10 U.S. and foreign issued patents and more than 20 pending U.S. and foreign applications.

• Lead Program
• Mechanisms of Action
• Safety
• Optimized Administration
• Clinical Status
• Intellectual Property

"MacuSight possesses a broad and strong intellectual property position for the use of sirolimus in the eye."